Hello, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. Our short person has left for the local schoolhouse for another day of learning and the official mascot is snoozing comfortably in a designated quiet corner. As for us, we are downing needed cups of stimulation — peppermint mocha is our preferred choice, so far — as we prepare for another round of phone calls and research. Meanwhile, we have assembled the usual menu of items to keep you engaged. Hope your day goes well and, as always, keep us in mind when something saucy occurs.

Several generic drug makers have held talks with the Department of Justice in the past six months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to Bloomberg News. Among the possible outcomes that have been discussed are deferred prosecution agreements in which the companies would admit to certain allegations but would be shielded from indictment in exchange for cooperating with the investigation and paying fines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy